BofA analyst Tazeen Ahmad raised the firm’s price target on Ascendis Pharma (ASND) to $242 from $230 and keeps a Buy rating on the shares. The firm’s survey of 26 endocrinologists who treat HPT patients on Yorvipath indicates growing uptake in Q3, says the analyst, who is “encouraged” by the continued positive real-world outlook for Yorvipath usage and looks for updated commentary from the company on payor coverage and trending discontinuation rate on the earnings call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma’s Promising Growth: Yorvipath Uptake and Anticipated TransCon CNP Approval Drive Buy Rating
- Ascendis Pharma initiated with a Strong Buy at Raymond James
- Ascendis Pharma Grants Employee Warrants to Boost Engagement
- Ascendis Pharma price target raised to $254 from $203 at Cantor Fitzgerald
- Ascendis Pharma Submits EMA Application for Achondroplasia Treatment